Immuron logo

Immuron(NASDAQ) IMRN

Market Cap$7.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-91%
5 Year-73%
1 Year-57%
1 Month-22%
$1.00
+2.91%
+0.03Today
Immuron last closing stock price
MetricPriceDate
Last closeUSD 0.972026-10-21
Immuron stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.83%USD 1.032026-10-14
1 month-21.77%USD 1.242026-09-21
3 month-17.09%USD 1.172026-07-23
Year to date+27.21%USD 0.762025-12-31
1 year-57.17%USD 2.272025-10-21
3 year-43.6%USD 1.722023-10-20
5 year-72.68%USD 3.552021-10-22
Since inception-90.74%USD 10.482017-03-02

Immuron Financials at a Glance

Market Cap

$7.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$12.63M

Net Income (TTM)

-A$7.96M

EPS (TTM)

-$0.34

P/E Ratio

-2.88

Dividend

$0.00

Beta (Volatility)

0.69 (Low)

Price

$1.00

Volume

11,996

Open

$0.93

Previous Close

$0.97

Daily Range

$0.93 - $1.04

52-Week Range

$0.68 - $2.25

Estimated Earnings Date

Feb 19, 2027

IMRN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Immuron

Immuron Limited is a biopharmaceutical company dedicated to the discovery, development, and commercialization of polyclonal antibodies. With operations in Australia, the United States, and other international markets, Immuron focuses on innovative healthcare solutions.

Products and Services
  • Travelan: An OTC medicine that reduces the risk of traveler's diarrhea
  • Protectyn: An immune supplement supporting digestive function and liver health
  • IMM-124E: A pipeline candidate in Phase III trials for anti-viral activity
Growth Outlook
  • Strong pipeline with IMM-529 targeting recurrent Clostridium difficile infections
  • Strategic collaborations with military research institutes enhance development capabilities
  • Potential market expansion as Travelan and Protectyn gain traction
Financial Highlights
  • Recent quarterly revenue of 3,579,052 AUD, showing growth potential
  • Cash and cash equivalents of 9,018,325 AUD, providing operational stability
  • Current ratio of 7.17 indicates strong liquidity position
Immuron Limited operates in the biotechnology sector, focusing on innovative healthcare solutions through its unique products. The company has established a solid foundation with its two marketed products, Travelan and Protectyn, which cater to significant health needs. The ongoing clinical trials for IMM-124E and IMM-529 highlight the company's commitment to advancing its product pipeline. The growth outlook for Immuron is promising, bolstered by strategic collaborations with reputable research institutions. These partnerships not only enhance the company's research capabilities but also position it favorably within the competitive landscape of biopharmaceuticals. As the company continues to develop its pipeline, there is potential for market expansion and increased revenue generation. Financially, Immuron demonstrates a robust liquidity position, with a current ratio significantly above 1, indicating the ability to meet short-term obligations. The recent quarterly revenue reflects the company's growth trajectory, while the substantial cash reserves provide a buffer for ongoing operations and development initiatives. Overall, Immuron Limited presents an intriguing opportunity within the biotechnology sector, driven by innovation and strategic partnerships.
AI Generated • Oct 18, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Steven Lydeamore, MBA

Website

www.immuron.com.au

Headquarters

Carlton, VIC 3053, AU

IMRN Financials

Key Financial Metrics (TTM)

Gross Margin

64.50%

Operating Margin

-61.39%

Net Income Margin

-49.77%

Return on Equity

-31.88%

Return on Capital

-42.08%

Return on Assets

-29.54%

Earnings Yield

-34.72%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$7.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

8.07M

Volume

12.00K

Avg. Volume

2.03M

Financials (TTM)

Gross Profit

A$8.12M

Operating Income

-A$8.97M

EBITDA

-A$8.95M

Operating Cash Flow

-A$6.41M

Capital Expenditure

-A$4.99K

Free Cash Flow

-A$6.42M

Cash & ST Invst.

A$9.02M

Total Debt

A$0.00

Immuron Performance Analysis

Immuron annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 1,214,033118.8%
20242024-06-30AUD 3,213,215164.7%
20252025-06-30AUD 4,719,28846.9%
20262026-06-30AUD 5,226,91310.8%
Immuron sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-03-31-58.8%
Q42025-06-30100.0%
Q22025-12-31N/A
Q42026-06-30N/A
Immuron annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.4522.9%
20242024-06-30AUD -0.8078.4%
20252025-06-30AUD -0.59-26.7%
20262026-06-30AUD -0.34-42.6%
Immuron sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-03-3146.3%
Q42025-06-30-103.4%
Q22025-12-31N/A
Q42026-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$3.58M

-10.4%

Gross Profit

A$2.35M

-11.4%

Gross Margin

65.78%

N/A

Market Cap

$7.83MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.12M

N/A

Employees

7

N/A

Net Income

-A$1.95M

+21.8%

EBITDA

-A$2.46M

+2.1%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$9.02M

+16.6%

Total Debt

A$0.00

-100.0%

Accounts Receivable

A$1.25M

+8.9%

Inventory

A$2.27M

+49.9%

Long Term Debt

A$0.00

-100.0%

Short Term Debt

A$0.00

-100.0%

Return on Assets

-29.54%

N/A

Return on Invested Capital

-42.25%

N/A

Free Cash Flow

-A$767.38K

+80.8%

Operating Cash Flow

-A$767.06K

+80.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BOLTBolt Biotherapeutics, Inc.
$4.06-1.93%
IMNNImunon, Inc.
$1.21+1.68%
TRAWTraws Pharma, Inc.
$0.37-1.01%
APMAptorum Group Limited
$8.26-14.84%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$7.91-14.49%
SPCXSpace Exploration Technologies
$145.55-8.64%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$83.40-19.22%
TSLGThemes ETF Trust - Leverage Shares 2x Long Tsla Daily ETF
$5.04-4.37%

Questions About IMRN

What is the current price of Immuron?

Immuron is trading at $1.00 per share.

What is the 52-week range for Immuron?

Over the past 52 weeks, Immuron has traded between $0.68 and $2.25.

How much debt does Immuron have?

As of the most recent reporting period, Immuron reported total debt of A$0.00.

How much cash does Immuron have on hand?

Immuron reported A$6.25M in cash and cash equivalents in its most recent financial results.

What is Immuron’s dividend yield?

Immuron does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services